| Literature DB >> 27266702 |
Hsin-Fu Lin1,2, Kang Tung3, Chun-Chung Chou4, Ching-Che Lin5, Jaung-Geng Lin6, Hirofumi Tanaka7.
Abstract
BACKGROUND: Muscle damage induced by unaccustomed or eccentric exercise results in delayed onset vascular stiffening. We tested the hypothesis that a 7-day supplementation of panax ginseng and salvia miltiorrhiza prior to an acute eccentric exercise could attenuate arterial stiffening.Entities:
Keywords: arterial stiffness; inflammation; muscle damage
Mesh:
Year: 2016 PMID: 27266702 PMCID: PMC4895816 DOI: 10.1186/s12906-016-1139-4
Source DB: PubMed Journal: BMC Complement Altern Med ISSN: 1472-6882 Impact factor: 3.659
Quantitative analyses of major compounds of the herb supplement used in the present study
| Compound | Content (mg/g) | |
|---|---|---|
|
| Rb1 | 2.24 |
| Re | 1.13 | |
| Rg1 | 1.47 | |
|
| Salvianolia acid B | 28.2 |
| Tanshinone IIA | 0.6 |
Fig. 1High-performance thin-layer chromatography fingerprints of Panax ginseng (a) and Salvia miltiorrhiza (b)
Fig. 2Study flow chart
Selected subject characteristics
| Placebo | Herb | |
|---|---|---|
| ( | ( | |
| Age, yr | 24 ± 1 | 26 ± 5 |
| Height, cm | 173 ± 1 | 174 ± 3 |
| Body mass, kg | 68 ± 2 | 68 ± 3 |
| BMI, kg/m2 | 23 ± 1 | 22 ± 1 |
| Body fat percentage, % | 19 ± 1 | 18 ± 2 |
| Waist-hip ratio | 0.85 ± 0.01 | 0.85 ± 0.01 |
| Heart rate at rest, bpm | 67 ± 3 | 58 ± 3 |
| Systolic BP, mmHg | 118 ± 2 | 112 ± 3 |
| Diastolic BP, mmHg | 66 ± 2 | 62 ± 2 |
| VO2peak, ml/kg/min | 47 ± 2 | 47 ± 2 |
| HDL cholesterol, mg/dL | 53 ± 2 | 53 ± 3 |
| LDL cholesterol, mg/dL | 97 ± 9 | 86 ± 5 |
| Total cholesterol, mg/dL | 180 ± 9 | 192 ± 8 |
| Triglyceride, mg/dL | 78 ± 9 | 58 ± 8 |
| HbA1C, % | 5.4 ± 0.1 | 5.4 ± 0.1 |
Values are means ± SEM
BMI body mass index, BP blood pressure, VO peak peak oxygen consumption, HbA1c glycosylated hemoglobin A1c
Fig. 3Delayed onset muscle soreness (a) and active range of motion (AROM) (b) following downhill running exercise. *P < 0.05 vs. Pre in the same condition
Fig. 4Relative changes in serum creatine kinase (CK) concentration in response to eccentric exercise sessions. *P < 0.05 vs. Pre in the same condition. †P < 0.05 vs. Placebo at the same time point
Fig. 5Effects of Chinese herb supplementation on carotid-femoral pulse wave velocity (cfPWV). *P < 0.05 vs. Pre. †P < 0.05 vs. Herb supplementation
Hemodynamic responses in control (seated rest) and eccentric exercise sessions
| Pre | 90 min | 24 h | 48 h | 72 h | ||
|---|---|---|---|---|---|---|
|
| ||||||
| Placebo | Control | 530 ± 19 | 535 ± 17 | 546 ± 16 | 547 ± 15 | 513 ± 13 |
| Exercise | 531 ± 12 | 548 ± 19 | 577 ± 20* | 570 ± 24 | 552 ± 22 | |
| Herb | Control | 482 ± 14 | 491 ± 17 | 490 ± 14 | 487 ± 13 | 505 ± 19 |
| Exercise | 523 ± 20 | 497 ± 17 | 503 ± 16 | 500 ± 13 | 505 ± 23 | |
|
| ||||||
| Placebo | Control | 63 ± 4 | 58 ± 3 | 62 ± 3 | 66 ± 3 | 65 ± 3 |
| Exercise | 62 ± 3 | 69 ± 4* | 66 ± 3 | 63 ± 3 | 59 ± 5 | |
| Herb | Control | 57 ± 3 | 54 ± 1 | 56 ± 3 | 59 ± 4 | 55 ± 3 |
| Exercise | 56 ± 2 | 65 ± 4* | 56 ± 3 | 55 ± 2 | 53 ± 3 | |
|
| ||||||
| Placebo | Control | 119 ± 2 | 116 ± 2 | 118 ± 2 | 119 ± 2 | 119 ± 2 |
| Exercise | 119 ± 2 | 114 ± 2 | 120 ± 2 | 120 ± 3 | 117 ± 2 | |
| Herb | Control | 114 ± 2 | 111 ± 2 | 114 ± 2 | 115 ± 3 | 115 ± 2 |
| Exercise | 116 ± 3 | 114 ± 3 | 115 ± 2 | 112 ± 2 | 111 ± 3 | |
|
| ||||||
| Placebo | Control | 66 ± 2 | 67 ± 1 | 67 ± 2 | 64 ± 2 | 67 ± 2 |
| Exercise | 66 ± 3 | 65 ± 2 | 65 ± 3 | 66 ± 2 | 64 ± 2 | |
| Herb | Control | 63 ± 3 | 63 ± 1 | 62 ± 2 | 62 ± 1 | 62 ± 1 |
| Exercise | 63 ± 3 | 61 ± 2 | 62 ± 1 | 63 ± 3 | 60 ± 1 | |
|
| ||||||
| Placebo | Control | 52 ± 2 | 49 ± 1 | 51 ± 2 | 55 ± 2 | 53 ± 2 |
| Exercise | 53 ± 2 | 48 ± 2 | 55 ± 2 | 53 ± 2 | 53 ± 1 | |
| Herb | Control | 51 ± 3 | 48 ± 3 | 52 ± 3 | 54 ± 3 | 53 ± 3 |
| Exercise | 53 ± 3 | 52 ± 3 | 53 ± 2 | 49 ± 3 | 51 ± 3 | |
Values are means ± SEM
cfPWV carotid-femoral pulse wave velocity, BP blood pressure
*P<0.05 vs. Pre in the same condition
Fig. 6Changes in flow-mediated vasodilatation in response to the eccentric exercise
Changes in muscle damage markers, inflammatory and oxidative stress markers in response to downhill running exercise in the placebo and herb group
| Pre | 90 min | 24 h | 48 h | 72 h | |
|---|---|---|---|---|---|
|
| |||||
| CRP, mg/dL | |||||
| Control | 0.07 ± 0.04 | 0.07 ± 0.04 | 0.07 ± 0.03 | 0.06 ± 0.02 | 0.05 ± 0.02 |
| Exercise | 0.08 ± 0.02 | 0.11 ± 0.05 | 0.15 ± 0.05* | 0.11 ± 0.05 | 0.10 ± 0.03 |
| CK, U/L | |||||
| Control | 94 ± 10 | 98 ± 8 | 89 ± 8 | 87 ± 9 | 90 ± 11 |
| Exercise | 93 ± 8 | 126 ± 13 | 396 ± 72*, ** | 257 ± 48*, ** | 192 ± 32* |
|
| |||||
| CRP, mg/dL | |||||
| Control | 0.13 ± 0.05 | 0.14 ± 0.05 | 0.11 ± 0.04 | 0.11 ± 0.04 | 0.11 ± 0.03 |
| Exercise | 0.10 ± 0.03 | 0.09 ± 0.03 | 0.15 ± 0.03* | 0.10 ± 0.02 | 0.10 ± 0.02 |
| CK, U/L | |||||
| Control | 110 ± 12 | 108 ± 9 | 119 ± 17 | 109 ± 11 | 113 ± 16 |
| Exercise | 106 ± 9 | 195 ± 51* | 291 ± 35*, ** | 204 ± 26*, ** | 151 ± 20 |
| TBARs, μM | |||||
| Placebo | 7.1 ± 1.1 | 8.1 ± 1.5 | 7.9 ± 1.0 | 6.5 ± 1.0 | - |
| Herb | 7.0 ± 1.0 | 6.6 ± 0.8 | 8.1 ± 0.9 | 5.7 ± 0.6 | - |
| IL-6, pg/ml | |||||
| Placebo | 0.44 ± 0.1 | 0.69 ± 0.1* | 0.32 ± 0.1 | 0.46 ± 0.1 | - |
| Herb | 0.50 ± 0.2 | 0.45 ± 0.1 | 0.23 ± 0.1* | 0.29 ± 0.1 | - |
| TNF-α, pg/ml | |||||
| Placebo | 0.45 ± 0.14 | 0.28 ± 0.06 | 0.30 ± 0.06 | 0.30 ± 0.06 | - |
| Herb | 0.44 ± 0.06 | 0.34 ± 0.06 | 0.38 ± 0.08 | 0.34 ± 0.06 | - |
Values are means ± SEM. TBARs, IL-6, and TNF-α were measured only during the eccentric exercise session
CRP C-reactive protein, CK creatine kinase, TBARs thiobarbituric acid reactive substances, IL-6 interleukin-6, TNF-α tumor necrosis factor-α
*P<0.05 vs. Pre in the same condition. **P<0.05 vs. Control or Placebo at the same time point
Associations between relative changes (%) in arterial stiffness and selected biomarkers
| ΔcfPWV 24 h | ΔcfPWV 48 h | |
|---|---|---|
| ΔCK | 0.05 | 0.08 |
| CRP | 0.17 | 0.21 |
| ΔIL-6 | 0.11 | 0.46* |
| ΔTNF-α | 0.60* | 0.57* |
| ΔTBARs | 0.09 | 0.36 |
cfPWV carotid-femoral pulse wave velocity, CK creatine kinase, CRP C-reactive protein, IL-6 interlukin-6, TNF-α tumor necrosis factor-α, TBARs thiobarbituric acid reactive substances
*P<0.05